TNS Targets Global Growth with Strategic Acquisition of AGNITY Global
Transaction Network Services (TNS) has today announced the acquisition of AGNITY Global, a leading provider of intelligent business communication applications and infrastructure to organizations in the telecommunications and healthcare industry verticals.
The move strategically enhances TNS’ Communications Market global capabilities through AGNITY’s established channel partnerships business model that spans more than 12 countries. It will also enable TNS’ existing customers to benefit from a broader portfolio of next generation solutions.
Headquartered in Silicon Valley with development and support operations in Richardson, Texas and Noida, India, AGNITY powers the networks of many global Tier-1 service providers via its scalable, carrier-grade Communication Application Server (CAS). This network agnostic, multi-service software platform offers app components and open APIs that enable service providers to address network technology transition challenges as well as future-proofing their infrastructure to more rapidly introduce new services.
“AGNITY is a perfect strategic fit for TNS as we seek to invest in and evolve our carrier service offerings, channel partnerships and development capabilities,” said Bill Versen, President of TNS’ Communications Market business. “Combining AGNITY’s innovative technology with our proven solutions creates a superior portfolio that will enable us to help carriers modernize their networks and bridge legacy platforms with new technology, including 5G enablement services.”
Founded in 2008 by tech entrepreneur and CEO Sanjeev Chawla, AGNITY boasts 5G ready technology and has more than 30 out-of-the-box high value applications, including advanced call routing, evolved next gen intelligent networks and fraud protection. AGNITY’s Defend application combines call screening and audio CAPTCHA with a range of CDR, speech and biometric analysis to identify, filter and block fraudulent calls as required. AGNITY FlexYcharge service is a real-time rating, charging and balance management service for voice, data, messaging across VoIP, IMS and Legacy networks.
“Our objective has always been to facilitate telecom network transformation through efficient, future-proofed applications and adoption of the latest technologies,” said Mr. Chawla, who is remaining with the company as Chief Technology Officer for TNS’ Communications Market business, reporting to Mr. Versen. “Creating the AGNITY CAS, a single platform for legacy, LTE/IMS, 5G and Cloud hosted networks, has brought significant revenue opportunities, efficiency gains and operational cost reduction to our customers. Now, as part of TNS’ large and established footprint, we look forward to bringing our joint capabilities to a wider audience.”
“We are excited to have Sanjeev and his talented team on board,” added Versen. “Sanjeev will play a major role in the development of TNS as we drive forward with our long-term growth vision, including the introduction of our award-winning identity and protection solutions to the global marketplace. We will also now be able to conduct near 24/7 development with resources in the US and India focused on innovating and rolling out our products faster than ever before.”
TNS, a subsidiary of Koch Equity Development, is a leading global provider of Infrastructure-as-a-Service solutions to the communications, payments and financial markets. Its pioneering Communications Market business has been a continuous innovator interconnecting carrier networks efficiently, securely and reliably. Its solutions range from call analytics, which identifies unwanted robocalls while enabling enhanced mobile identity for legitimate callers, to interoperability, mobile roaming, clearing and settlement, and analytics for LTE and 5G.
Terms of the deal were not disclosed.
About Transaction Network Services
Established more than 30 years ago, TNS’ extensive portfolio of innovative, value-added services now supports thousands of organizations across more than 60 countries to interact efficiently, conduct mission critical processes securely and adopt new technologies flexibly. For more information, please visit tnsi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005287/en/
Contact information
Company:
TNS
Clare Cockroft
703-814-8065
pr@tnsi.com
Or
Media:
Bluetext for TNS
Brian Lustig
202-836-9112
tns@bluetext.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press Release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press Release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press Release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press Release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom